Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary Fujian Shendi Pharmaceutical Co., Ltd. recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for HRS-7249 injection. After review, the clinical trial application for HRS-7249 injection submitted on April 2, 2024 for the treatment of hyperlipidemia meets the relevant requirements for drug registration. The approval allows the drug to be used in clinical trials.

HRS-7249 injection is an innovative drug of the first category independently developed by the company. Non-clinical efficacy studies have shown that HRS-7249 can effectively and durably reduce triglycerides in the body. Non-clinical safety evaluation studies have shown that HRS-7249 has a low off-target risk and good safety. According to research, there is currently no similar product approved for sale at home or abroad. As of now, the accumulated research and development cost for HRS-7249 injection related projects is approximately 62.03 million yuan.